RT Journal Article SR Electronic T1 Making the case for investing in suicide prevention interventions: estimating the economic impact of suicide and non-fatal self harm events JF Injury Prevention JO Inj Prev FD BMJ Publishing Group Ltd SP A257 OP A258 DO 10.1136/ip.2010.029215.916 VO 16 IS Suppl 1 A1 McDaid, D A1 Bonin, E A1 Park, A A1 Hegerl, U A1 Arensman, E A1 Kopp, M A1 Gusmao, R YR 2010 UL http://injuryprevention.bmj.com/content/16/Suppl_1/A257.3.abstract AB Background Reducing the rate of suicide remains a key public health goal. This paper estimates the lifetime costs of suicide and non-fatal self harm events in four European countries (Germany, Hungary, Ireland and Portugal) participating in the Optimising Suicide Prevention in Europe (OSPI) project. It then looks at what level of suicide reduction would need to be achieved for an area based suicide prevention intervention to be considered cost-effective. Methods Different elements of cost: direct costs (eg, police, funeral services, healthcare use), lost productivity and intangible costs of pain, grief and premature loss of life are described. Data on suicide rates and non-fatal suicide attempts, life expectancy and economic activity in Germany, Hungary, Ireland and Portugal are then used to model the lifetime costs. Decision modelling techniques are used to determine the effectiveness threshold required for a multi-level community based prevention intervention, such as that used in the OSPI project, to be considered cost-effective. Results The costs of suicide are substantial and impact across sectors. The average lifetime costs of each completed suicide are around 2 million in EU countries. Increasingly policy makers want to know not only about effectiveness but also the cost effectiveness of interventions when determining how best to make use of budgets. Our analysis suggests that if an area-wide suicide prevention intervention were to achieve only a modest 1% reduction rate in the number of suicides, in most scenarios this remains highly cost-effective.